Eric P. Lefkofsky Sells 84,948 Shares of Tempus AI, Inc. (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) CEO Eric P. Lefkofsky sold 84,948 shares of the firm's stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $70.02, for a total value of $5,948,058.96. Following the completion of the transaction, the chief executive officer now owns 5,208,057 shares in the company, valued at $364,668,151.14. The trade was a 1.60 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Tempus AI Price Performance

NASDAQ TEM traded up $5.69 during trading on Monday, hitting $89.44. The stock had a trading volume of 25,048,636 shares, compared to its average volume of 12,947,475. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. The firm has a 50 day moving average price of $47.46 and a 200 day moving average price of $50.72. Tempus AI, Inc. has a twelve month low of $22.89 and a twelve month high of $91.45.

Hedge Funds Weigh In On Tempus AI

Institutional investors have recently bought and sold shares of the company. First Horizon Advisors Inc. acquired a new position in Tempus AI in the 3rd quarter valued at about $30,000. Operose Advisors LLC acquired a new position in shares of Tempus AI during the fourth quarter worth about $25,000. Farther Finance Advisors LLC acquired a new position in shares of Tempus AI during the fourth quarter worth about $34,000. Prestige Wealth Management Group LLC grew its position in shares of Tempus AI by 910.4% during the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company's stock worth $36,000 after buying an additional 965 shares in the last quarter. Finally, NewEdge Advisors LLC acquired a new position in shares of Tempus AI during the fourth quarter worth about $49,000. 24.22% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Needham & Company LLC restated a "buy" rating and issued a $56.00 price objective on shares of Tempus AI in a report on Tuesday, January 14th. Wolfe Research started coverage on shares of Tempus AI in a report on Friday, December 13th. They issued an "outperform" rating and a $60.00 price objective on the stock. Stifel Nicolaus lowered shares of Tempus AI from a "buy" rating to a "hold" rating and boosted their price objective for the company from $45.00 to $65.00 in a report on Monday, November 11th. Bank of America boosted their price objective on shares of Tempus AI from $52.00 to $54.00 and gave the company a "neutral" rating in a report on Friday, December 13th. Finally, Piper Sandler restated a "neutral" rating and issued a $70.00 price objective (up from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $58.55.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.